Skip to main content
AmigoFish

Pharmaceutical Executive Daily: FDA Approves Fayuvi

From Pharmaceutical Executive · · 3 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.

Back to Pharmaceutical Executive · Report a problem